Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multi-center Study of the Safety and Efficacy of ADX-N05 in the Treatment of Excessive Daytime Sleepiness in Subjects With Narcolepsy

Trial Profile

A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multi-center Study of the Safety and Efficacy of ADX-N05 in the Treatment of Excessive Daytime Sleepiness in Subjects With Narcolepsy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 29 May 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Solriamfetol (Primary)
  • Indications Narcolepsy
  • Focus Therapeutic Use
  • Sponsors Aerial BioPharma; Jazz Pharmaceuticals Inc
  • Most Recent Events

    • 02 Jun 2014 Primary endpoint has been met according to a Jazz Pharmaceuticals media release (Evaluate the Clinical Global Impression-Change scores).
    • 02 Jun 2014 Primary endpoint has been met according to a Jazz Pharmaceuticals media release (Evaluate the change from Baseline in the average sleep latency time (in minutes) as determined from the Maintenance of Wakefulness Test).
    • 02 Jun 2014 Results published in a Jazz Pharmaceuticals media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top